Genflow Biosciences PLC Announces 2024 Highlights
Genflow Biosciences Plc("Genflow" or "the Company")A Look Back at an Exciting 2024 LONDON, UNITED KINGDOM / ACCESSWIRE / January 6,...
Vaccine
Announcing the Launch of Relax VR-3: A Game-Changing Upgrade for Immersive Relaxation Experiences
SAN FRANCISCO, Jan. 2, 2025 /PRNewswire/ -- Relax VR, a leader in multisensory virtual reality relaxation solutions, proudly announces the...
Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO...
Defence Arranges Financing
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
Hamilton, Bermuda, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Further proof of great versatility of Altamira’s platform for extrahepatic RNA deliveryCircular...
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuationsEnrollment to be extended...
Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV
Current Renovaro Chairman to Lead Subsidiary’s Development Program and Commercialization LOS ANGELES and AMSTERDAM, Dec. 30, 2024 (GLOBE NEWSWIRE) --...
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfolio...
Rapid Dose Announces Proposed Issuance of Shares as Payment of Director Fees
Burlington, Ontario--(Newsfile Corp. - December 24, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announces that it...
ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most advanced next generation pertussis vaccine,...
ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most advanced next generation pertussis vaccine,...
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
SHELTON, CT / ACCESSWIRE / December 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), says that its broad-spectrum antiviral...
DeepIntent’s HealthFirst Vaccine Audiences Named One of the Most Interesting Innovations of 2024 by PM360
NEW YORK, Dec. 20, 2024 /PRNewswire/ -- PM360, a leading trade magazine for marketing decision-makers in the pharmaceutical, biotech, medical device,...
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank
Funds expected to be used to advance IO Biotech’s immune-modulating therapeutic cancer vaccines, including potential BLA submission for IO102-IO103 in...
Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the...
GenBio AI Releases Phase 1 of World’s First Digital Organism to Transform Medical Research
PALO ALTO, Calif., Dec. 19, 2024 /PRNewswire/ -- Just as the transistor and microscope unlocked new waves of discovery, today,...
Black Book Market Research Releases Global Survey Findings on Population Health Applications in Emerging Markets
LONDON, UNITED KINGDOM / ACCESSWIRE / December 19, 2024 / Black Book Market Research, a leading global healthcare technology research...
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer
Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration...
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA
- Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies...
ENA Respiratory Announces Peer-Reviewed Publication of First Time in Humans and Influenza Virus Challenge Studies with the Intranasal Innate Immunomodulator INNA-051
When compared to placebo, prophylactic administration of INNA-051 was associated with significantly increased expression of multiple host defense genes and...